Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ImmunoGen, Inc. Announces Proposed Public Offering of Common Stock
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN) announced today that it intends to offer for sale its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be
Toggle Summary ImmunoGen, Inc. Initiates Phase I Trial of IMGN853 in Ovarian Cancer and Other Solid Tumors Over-Expressing Its Folate Receptor Target
— Folate receptor 1 (FOLR1)-targeting compound is second novel ImmunoGen product candidate to enter clinic this year — WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops anticancer therapeutics using its antibody expertise and Targeted Antibody